Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	15.84B -13.7%
Revenue (ttm)	6.37B +11.4%
Net Income	806.68M +13.6%
EPS	1.49 +5.9%
Shares Out	539.68M
PE Ratio	19.68
Forward PE	n/a
Dividend	0.79 (2.70%)
Ex-Dividend Date	Jul 17, 2026

Volume	2,186,492
Open	29.20
Previous Close	29.20
Day's Range	28.75 - 29.35
52-Week Range	27.55 - 36.86
Beta	-0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2025, Synmosa Biopharma's revenue was 6.19 billion, an increase of 11.53% compared to the previous year's 5.55 billion. Earnings were 821.85 million, an increase of 20.03%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 29, 2026

Data Sources Report a data error